---
document_datetime: 2023-09-21 20:29:03
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/orladeyo-epar-all-authorised-presentations_en.pdf
document_name: orladeyo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8811873
conversion_datetime: 2025-12-20 01:54:11.362288
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Annex A

<div style=\"page-break-after: always\"></div>

| EMA Number       | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging      | Pack size   |
|------------------|-------------------|------------|-----------------------|---------------------------|--------------------------|-------------|
| EU/1/21/1544/001 | Orladeyo          | 150 mg     | Capsule, hard         | Oral use                  | blister (PCTFE/PVC- Alu) | 28 capsules |
| EU/1/21/1544/002 | Orladeyo          | 150 mg     | Capsule, hard         | Oral use                  | blister (PCTFE/PVC- Alu) | 98 capsules |